ATRIAL FIBRILLATION MARKET ANALYSIS

Atrial Fibrillation Market Size and Trends

The Global Atrial Fibrillation Market is estimated to be valued at USD 24.61 Bn in 2024 and is expected to reach USD 40.11 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7.2% from 2024 to 2031.

Key Takeaways of Atrial Fibrillation Market:

• Based on type, the paroxysmal atrial fibrillation segment is expected to contribute the highest share of the market with 43.1% in 2024
• Based on treatment, the pharmacological treatments segment is expected to contribute the highest share with 53.1% in 2024
• Based on technology, the radiofrequency segment is expected to contribute the highest share of the global atrial fibrillation market with 30.1% in 2024
• North America is expected to top the global market with 35.3% share, followed by Asia Pacific with 27.7% share in 2024

Market Overview:

Atrial fibrillation is one of the most common heart conditions that can increase the risk of strokes, heart failure, and other complications. The growing geriatric population remains one of the key factors driving the increased demand for diagnosis and treatment of atrial fibrillation worldwide. The global atrial fibrillation market is expected to witness a positive growth trend over the forecast period. There is an increased adoption of novel procedures such as cryoablation for the treatment of atrial fibrillation which is expected to provide opportunities for market growth. Furthermore, developments in catheter ablation technologies that ensure faster treatment and better outcomes for patients are increasing the preference for minimally invasive surgeries over pharmacological treatments.

To learn more about this report, Request sample copy

Key Developments:

• In November 2024, Johnson & Johnson MedTech , a division of Johnson & Johnson, a global healthcare company, received U.S. FDA approval for the VARIPULSE Pulsed Field Ablation (PFA) Platform for treating drug-refractory paroxysmal Atrial Fibrillation (AFib). The VARIPULSE Platform is the first in the U.S. to integrate fully with the CARTO 3 Electro-anatomical Mapping System, enhancing efficiency, reproducibility, and accuracy in cardiac procedures.
• In November 2023, Bayer initiated the OCEANIC-AFINA Phase III study to evaluate asundexian (BAY2433334) as a treatment for atrial fibrillation (AF) patients aged ≥65 at high risk for stroke or embolism who cannot take oral anticoagulants due to bleeding risks. This complements the ongoing OCEANIC-AF study, aiming to provide comprehensive evidence of asundexian's efficacy and safety in stroke prevention across diverse AF patient groups.
• In November 2021, Medtronic India, a MedTech company, took a significant step in advancing atrial fibrillation treatment with the launch of its Arctic Front Cardiac Cryoablation Catheter System. This innovative product is designed specifically for pulmonary vein isolation, effectively blocking unwanted electrical signals and providing a reliable solution for managing atrial fibrillation.

Top Strategies Followed by Global Atrial Fibrillation Market Players

• Leading companies in the atrial fibrillation industry prioritize extensive research and development to innovate high-performance products
  • For instance, Boston Scientific reported a significant increase in electrophysiology sales, reaching US$ 439 million in Q3 2024, indicating substantial investment in developing advanced atrial fibrillation treatments
• Mid-level players focusing on initiative which is expected to fuel market growth by increasing awareness and acceptance of ablation procedures among healthcare providers and patients
  • For instance, in April 2024, the European Heart Rhythm Association (EHRA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Latin American Heart Rhythm Society (LAHRS) have jointly issued an expert consensus statement on catheter and surgical ablation of atrial fibrillation. The document offers updated guidance on best practices, techniques, and patient selection for atrial fibrillation ablation, enhancing global treatment outcomes.
• Small-scale players focus on niche areas not addressed by large vendors. AfibCor specializes in wearable devices to detect irregular heart rhythms and has partnered with rural clinics and Telehealth networks to monitor cardiac patients remotely. In June 2024, ReactHealth developed a patch based on flexible hybrid electronics that can accurately monitor heart activity during intense workouts. Such niche innovation and local partnerships enable new entrants to gain traction.

Emerging Startups - Global Atrial Fibrillation Industry Ecosystem

• Several startups are developing innovative technologies to transform the market. Heartbeat Labs has created an AI-powered smart stethoscope and mobile app that uses deep learning algorithms to analyze heart sounds and flag abnormalities within minutes. Biosense has developed novel catheter tip sensors that can map heart chambers in high resolution to guide more precise ablation procedures. Such advanced technologies have the potential to facilitate faster diagnostics, personalized treatment planning and better clinical outcomes.
• Sustainability is another area attracting startups. FibroNano develops biodegradable ablation catheters made from polylactic acid that eliminate hazardous medical waste. MediSense uses discarded coffee grounds and plant fibers to create eco-friendly electrode materials. These innovations are designed to minimize the environmental footprint of industries. Additionally, startups such as Aflare and Cardiac Insight are making significant strides by targeting underserved patient populations with portable monitoring solutions and cost-effective care models, thereby contributing to expanded healthcare access.